About this medicine

Metformin supports glucose control; it is not an antipsychotic or a direct treatment for psychosis. Its psychiatric relevance includes physical-health effects of antipsychotic treatment.

Weight change can affect physical health, comfort and willingness to continue psychiatric treatment. Discuss it early and without blame. The aim is to protect metabolic health while maintaining effective mental-health care, not to treat an arbitrary weight number or replace nutrition, activity and practical support.

What is this medicine used for?

The checked Brown & Burk immediate-release tablet treats type 2 diabetes when diet and exercise do not adequately control glucose. Antipsychotic-related weight-gain prevention or management is off-label, even when the person also receives psychiatric care through the NHS.

Glucophage SR has specific adult licences for type 2 diabetes, reducing or delaying diabetes onset in defined high-risk patients despite intensive lifestyle change, and supporting ovulation in PCOS. These product-specific licences must not be generalised to every metformin preparation or described as approval for antipsychotic weight gain.

UK services use differing protocols. Nottinghamshire guidance considers metformin after lifestyle measures and other options have been explored; any antipsychotic switch must balance metabolic benefit against relapse risk. Gloucestershire's local guidance also requires explanation of off-label use, an agreed trial and review of benefit. Local formulary inclusion does not guarantee identical access throughout the UK.

A research-derived prevention guideline proposes earlier metformin with high-risk antipsychotics, or when early weight gain and other risk factors indicate increased risk. Its recommendations include low-certainty evidence and expert consensus; this is not an MHRA licence, a NICE mandate or proof that every NHS service uses the same threshold. Preventing further gain and reversing established gain are related but different treatment goals.

Which warning signs need help?

Lactic acidosis is rare but serious. Marked weakness with vomiting, abdominal pain or breathing difficulty needs urgent assessment. Dehydrating illness, severe infection or oxygen deprivation requires prompt advice about the treatment plan.

Known mitochondrial disorders, including MELAS or maternally inherited diabetes and deafness, need special attention. Severe dehydration calls for the product's temporary-stop advice and prompt professional guidance. This is distinct from routine mild stomach upset.

How do I take it safely?

For adults with normal kidney function, the Brown & Burk diabetes reference starts at 500 or 850 mg two or three times daily with meals and adjusts after 10–15 days. This describes the named diabetes product, not a psychiatric weight-management starting regimen.

Glucophage SR is a prolonged-release tablet generally started at 500 mg once daily with the evening meal, then adjusted using its own instructions. The 750 and 1000 mg strengths are intended for patients already taking metformin. A slower-release formulation may be considered when immediate-release treatment is poorly tolerated.

As a local off-label example, Gloucestershire guidance starts low, for example 500 mg daily, and increases gradually as tolerated towards 1.5–2 g/day. Kidney function, tolerability and the reason for treatment can change what is appropriate. This illustrates one specialist protocol, not a recommendation for a reader to start or titrate metformin.

Metformin Colonis 500 mg/5 mL oral solution is a measured liquid option. Its product information has its own renal restrictions and directions. Neither a household spoon nor another liquid's concentration is an acceptable substitute for the supplied measuring device and prescription label.

What side effects should I know about?

Nausea, diarrhoea, abdominal discomfort, taste change and reduced appetite can occur. Take persistent symptoms seriously; dosing formulation or other causes may need review.

Who needs extra care with this medicine?

Kidney disease, severe infection, liver disease and heavy alcohol intake increase concern. Tell clinicians before surgery or contrast imaging because temporary interruption may be necessary.

Can it affect my other medicines?

Medicines affecting kidney function, including some diuretics and NSAIDs, require review. Insulin or other glucose-lowering drugs can change hypoglycaemia risk; do not assume metformin alone explains every symptom.

What check-ups will I need?

Check kidney function before treatment and periodically. MHRA advises testing B12 when deficiency is suspected and considering periodic checks for people at risk, especially with higher doses or longer use.

The checked product calls for kidney assessment at least annually, more frequently with older age or deterioration. Monitor glucose and other metabolic measures as appropriate to the reason for treatment; a weight benefit does not remove other antipsychotic monitoring.

For psychiatric weight-gain use, agree baseline measurements and a realistic outcome before the trial: weight trajectory, glucose/HbA1c and other antipsychotic physical-health monitoring remain important. The Gloucestershire protocol reviews clinical benefit at about 12 weeks and reassesses continuation if the antipsychotic changes or the weight benefit is lost. That is a local review framework, not a universal NHS rule.

Improved weight alone does not justify indefinite treatment without review. Discuss tolerability, adherence, the person's goals and whether prevention of further gain is a meaningful benefit. Research prevention recommendations should not be confused with a guaranteed amount of weight loss in an individual.

What about pregnancy, breastfeeding and age?

The immediate-release diabetes licence starts at age 10; Glucophage SR says it should not be used in children because of absent data. Neither statement establishes a childhood psychiatric weight-management licence. Use in a child or young person needs an appropriate specialist decision and formulation-specific review.

Pregnancy prescribing is assessed against the underlying indication and maternal needs. In PCOS, restoration of ovulation can allow pregnancy; metformin is not contraception. A diabetes or fertility indication does not establish that an off-label weight-management prescription should automatically continue through pregnancy.

Breastfeeding advice differs. The reviewed product leaflets/SmPCs are restrictive, while NHS information and SPS permit metformin during breastfeeding after assessment. SPS advice concerns healthy full-term infants and principally diabetes; it specifically recommends further advice for other indications. Monitor for gastrointestinal symptoms, unusual drowsiness and adequate infant weight gain, and seek specialist advice if the baby is premature or unwell.

What if I miss a dose or want to stop?

Do not double a missed dose. Stopping may worsen glucose control; seek advice about side effects and follow an agreed sick-day plan rather than making prolonged changes alone.

How does it work?

Metformin helps lower blood glucose, the sugar the body uses for fuel. It reduces how much glucose the liver makes and improves insulin sensitivity, meaning the body responds better to insulin. Insulin is a hormone, a chemical signal carried in the blood, that helps regulate blood sugar. Because metformin does not directly make the body release more insulin, it does not usually cause low blood glucose when taken on its own.

How the Body Manages Blood Sugar

The body gets glucose from food, and the liver can also make and release it. Insulin helps control how glucose is used and stored.

A hormone is a chemical message carried through the blood. When tissues respond less well to insulin, blood glucose can stay too high; this is called insulin resistance. Metformin acts on these processes across the body rather than primarily changing messages between brain cells.

What is known: Metformin’s established role is to improve blood-glucose control in type 2 diabetes.

What remains uncertain: This action does not establish a direct treatment effect on mental health symptoms.

How the process works

  1. Glucose regulation
  2. Whole-body health
  3. Clinical monitoring
Metformin’s established role is to improve blood-glucose control in type 2 diabetes. Simplified illustration of the process; individual responses vary.
About this illustration

Glucose regulation; Whole-body health; Clinical monitoring. This action does not establish a direct treatment effect on mental health symptoms.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Metformin reduces the liver’s glucose output and improves insulin sensitivity, meaning the body responds more effectively to the insulin it already has. The prescribing information also describes less glucose being absorbed from the intestine, part of the gut. Together, these effects can lower high blood glucose without directly stimulating extra insulin release.

What is known: Several effects in different organs contribute to glucose control.

What remains uncertain: These effects cannot tell us exactly how an individual’s weight will change.

How the process works

  1. Liver glucose
  2. Insulin sensitivity
  3. Glucose control
Several effects in different organs contribute to glucose control. Simplified illustration of the process; individual responses vary.
About this illustration

Liver glucose; Insulin sensitivity; Glucose control. These effects cannot tell us exactly how an individual’s weight will change.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

Metformin belongs to a family of medicines called biguanides, a name based on their chemical structure. Its effects involve several metabolic processes: the chemical reactions that help cells use and manage energy.

Researchers continue to study how these fit together. The kidneys remove metformin largely unchanged; this is called renal clearance. How well the kidneys work therefore affects how much medicine stays in the body.

What is known: The liver, gut, body tissues and kidneys each have a role in its action or removal.

What remains uncertain: One molecular explanation does not yet account for all of metformin’s effects.

How the process works

  1. Biguanide molecule
  2. Metabolic processes
  3. Renal clearance
The liver, gut, body tissues and kidneys each have a role in its action or removal. Simplified illustration of the process; individual responses vary.
About this illustration

Biguanide molecule; Metabolic processes; Renal clearance. One molecular explanation does not yet account for all of metformin’s effects.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Gastrointestinal effects are common early in treatment. Long-term B12 depletion can produce fatigue, nerve symptoms or cognitive difficulties, which should not automatically be attributed to a psychiatric disorder.

How does my body process it?

Metformin leaves the body unchanged through the kidneys. Reduced renal clearance raises exposure; the selected product contraindicates use below a GFR of 30 mL/min.

Renal wording is product-specific: the reviewed Colonis liquid contraindicates use below 45 mL/min, unlike the below-30 threshold in the reviewed tablet products. This discrepancy must be checked against the actual dispensed preparation, not silently averaged into a single cut-off.

How do treatment options differ?

Immediate-release, prolonged-release and liquid products differ in administration and sometimes licence wording. Changing formulation may help swallowing or tolerability, but requires attention to dose, age and kidney function.

Metformin is an adjunct rather than a replacement for psychological treatment or an antipsychotic. Lifestyle support and a review of medicines remain relevant; switching an effective antipsychotic solely for weight may carry relapse risk. Decisions about other weight-management medicines follow their own evidence, licences and access criteria.

A closer look at the science

Its actions involve liver, muscle and gut pathways, including AMPK-related signalling and glucose transport. These mechanisms are more complex than a single appetite-suppression target.

Metformin is a biguanide used in hydrochloride form. Glucose regulation differs from direct antipsychotic effects; the molecule does not show a product's release technology.

Chemical formula: C4H11N5 · HCl

The neutral parent contains 4 carbon, 11 hydrogen and 5 nitrogen atoms. Hydrochloride adds a salt component. The selected UK tablet's stated strength is hydrochloride mass, not neutral-parent mass.

PubChem neutral metformin structure, CID 4091; hydrochloride component omitted.
NCBI PubChem CID 4091. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

The parent-molecule drawing omits the hydrochloride component and cannot show differences between immediate-release and extended-release tablets.

How was this medicine developed?

In 2022, MHRA strengthened recognition of B12 deficiency as a common adverse effect. Current monitoring advice reflects this update rather than assuming an older diabetes profile remains sufficient.

Sources and References

  1. Metformin 500 mg film-coated tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. Metformin

    Scope: UK patient information.

  3. Metformin and reduced vitamin B12 levels: monitoring advice

    Scope: United Kingdom.

  4. South East London Joint Medicines Formulary: biguanides

    Scope: England, South East London only.

  5. Metformin 500 mg and 850 mg film-coated tablets: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  6. Antipsychotics prescribing guideline V2.3

    Scope: England, Nottinghamshire local guidance.

  7. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation

    Scope: Research-derived international expert guidance, not MHRA authorisation or UK national service policy.

  8. Glucophage SR 500 mg prolonged-release tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  9. Glucophage SR 500 mg, 750 mg and 1000 mg prolonged-release tablets: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  10. Antipsychotic weight-gain guideline CLG105 V1.1

    Scope: England, Gloucestershire local guidance.

  11. Metformin Colonis 500 mg/5 mL oral solution: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  12. Using antidiabetic medicines during breastfeeding

    Scope: UK specialist advice for full-term healthy infants; diabetes indication.

  13. Laurus metformin immediate-release and extended-release tablets: US prescribing information, July 2026

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  14. Metformin: patient information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?..

  15. Metformin: verified neutral parent, PubChem CID 4091

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  16. NIMH: Understanding psychosis

Shared scientific background. US product pharmacology and international chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top